[{"id":"67cbf364-5178-48ac-a2d4-4cfc52c84dd1","acronym":"","url":"https://clinicaltrials.gov/study/NCT05009953","created_at":"2021-08-18T15:53:39.772Z","updated_at":"2024-07-02T16:36:24.253Z","phase":"Phase 2","brief_title":"Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer","source_id_and_acronym":"NCT05009953","lead_sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd.","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e 5-fluorouracil • leucovorin calcium • Enshuxing (enlonstobart) • irinotecan liposomal"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 09/01/2021","start_date":" 09/01/2021","primary_txt":" Primary completion: 08/01/2023","primary_completion_date":" 08/01/2023","study_txt":" Completion: 08/01/2024","study_completion_date":" 08/01/2024","last_update_posted":"2021-09-20"},{"id":"8cc716fc-044d-449a-af10-d49c36af5fbc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05047991","created_at":"2021-09-17T19:53:35.072Z","updated_at":"2024-07-02T16:36:24.303Z","phase":"Phase 2","brief_title":"Study of Irinotecan Liposome Injection-containing Regimens Versus Nab-paclitaxel Plus Gemcitabine in Patients With Previously Untreated, Metastatic Pancreatic Adenocarcinoma","source_id_and_acronym":"NCT05047991","lead_sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd.","biomarkers":" UGT1A1","pipe":" | ","alterations":" UGT1A1*1*1","tags":["UGT1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e UGT1A1*1*1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • 5-fluorouracil • albumin-bound paclitaxel • oxaliplatin • leucovorin calcium • irinotecan liposomal"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 153","initiation":"Initiation: 10/01/2021","start_date":" 10/01/2021","primary_txt":" Primary completion: 11/01/2023","primary_completion_date":" 11/01/2023","study_txt":" Completion: 11/01/2024","study_completion_date":" 11/01/2024","last_update_posted":"2021-09-17"},{"id":"713c4248-5747-4d39-93b6-c4a7ef236f76","acronym":"","url":"https://clinicaltrials.gov/study/NCT04728035","created_at":"2021-01-28T12:53:00.378Z","updated_at":"2024-07-02T16:36:35.368Z","phase":"Phase 1","brief_title":"Study of Irinotecan Liposome Injection in Patients With Advanced Breast Cance","source_id_and_acronym":"NCT04728035","lead_sponsor":"CSPC Ouyi Pharmaceutical Co., Ltd.","biomarkers":" HER-2 • PD-L1 • BRCA1 • BRCA2","pipe":" | ","alterations":" BRCA2 mutation • BRCA1 mutation • HER-2 negative","tags":["HER-2 • PD-L1 • BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRCA2 mutation • BRCA1 mutation • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e irinotecan • irinotecan liposomal"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 136","initiation":"Initiation: 04/01/2021","start_date":" 04/01/2021","primary_txt":" Primary completion: 04/01/2023","primary_completion_date":" 04/01/2023","study_txt":" Completion: 04/01/2024","study_completion_date":" 04/01/2024","last_update_posted":"2021-01-29"}]